Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.
About us
Our vision at Immunocore is to continue to deliver transformational science that transforms lives.
Our technology
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
Pipeline
We have a robust pipeline of wholly owned and partnered programs to address a broad spectrum of disease indications.
Latest news
19 November 2018
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
26 October 2018
Immunocore CEO Andrew Hotchkiss appointed to the Board of the BIA
5 September 2018
Immunocore strengthens IP position in the field of TCR-based therapeutics
20 August 2018
Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours